viewInspiration Healthcare

Inspiration Heathcare establishes European presence through Bio-Med deal

IHC will service and repair Bio-Med's air/oxygen blenders across Europe

Other third party service deals in Europe are expected to follow

Inspiration Healthcare Group plc (LON:IHC) is to become a European service centre for Bio-Med Devices, a US specialist in critical care equipment.

IHC will service and repair Bio-Med's air/oxygen blenders across Europe, with other third party service deals in the continent expected to follow.

The signing of the agreement will also lead to a greater awareness of the use of air/oxygen blenders in intensive care and resuscitation, said IHC.

Neil Campbell, Inspiration Healthcare's chief executive, said: "We are very pleased to have signed this agreement with Bio-Med with whom we have been working for many years.

“This will allow us to improve significantly the level of servicing of these units as well as broadening our presence in European hospitals."

WH Ireland said the deal would appeal to both new buyers and current users as the presence of a good local service agent based in the UK will reduce shipping costs and result in quicker repair turnaround times.

The broker left its forecasts unchanged, its target price is 58p, but added that IHC had expanded its service offering while in turn cementing a distribution growth platform within Europe was an encouraging development.

IHC, which specialises in products for the neonatal market, joined AIM in May through a reverse takeover of heating products group Inditherm

Shares rose 1% to 39p.

Quick facts: Inspiration Healthcare

Price: 63 GBX

Market: AIM
Market Cap: £24.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Genprex sees newly licensed diabetes gene therapy as an...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed diabetes gene...

2 days, 17 hours ago

2 min read